Rationale Cannabinoid CB 1 receptor agonists vary in efficacy in vitro; however, relationships between efficacy and behavioral effects are unclear. Objective This study examined the relationship between apparent CB 1 agonist efficacy and in vivo effects. Methods Male C57BL/6J mice responded for food under a fixed ratio 30 schedule; rectal temperature was measured. Sensitivity of the mice to cannabinoid agonists (rank order efficacy in vitro reported to be CP 55940>anandamide>Δ 9 -tetrahydrocannabinol; Δ 9 -THC) and a non-cannabinoid (the benzodiazepine midazolam) was determined before, during, and after discontinuation of daily Δ 9 -THC treatment (32 mg/kg/day, i.p.). Rimonabant was combined with cannabinoids to examine whether CB 1 receptors mediated effects on response rate. Results Δ 9 -THC, CP 55940, anandamide, and midazolam decreased responding at doses smaller than those producing hypothermia. Rimonabant antagonized the rate-decreasing effects of Δ 9 -THC and CP 55940, but not those of anandamide. Δ 9 -THC treatment produced tolerance for both rate-decreasing and hypothermic effects. Δ 9 -THC treatment did not change sensitivity to the rate-decreasing effects of CP 55940, but produced cross-tolerance to CP 55940 for hypothermic effects. Δ 9 -THC treatment did not modify sensitivity to anandamide and midazolam. Conclusions CB 1 receptors mediate the operant ratedecreasing effects of Δ 9 -THC and CP 55940, but not anandamide, in mice. CB 1 agonist efficacy is an important determinant of in vivo effects, especially with regard to the magnitude of tolerance and cross-tolerance resulting from daily Δ 9 -THC treatment. This applies not only to different cannabinoids when measuring the same effect but also to the same cannabinoid when measuring different effects.
Introduction
Smoking or ingestion of Cannabis sativa preparations such as marijuana (leaves and flowering tops) can result in sedation, cognitive dysfunction, short-term memory disruption, altered time assessment, perceptual changes, motor incoordination, and impaired executive function (Dewey 1986; Hollister 1986; Pertwee 1988; Abood and Martin 1992) . The effects of Cannabis result from actions of Δ 9 -tetrahydrocannabinol (Δ 9 -THC) (Mechoulam and Gaoni 1965) . In addition to Δ 9 -THC, a number of structurally diverse cannabinoid agonists, some (e.g., anandamide) derived from brain and others (e.g., CP 55940) not found in nature, bind to two cannabinoid receptor subtypes: CB 1 and CB 2 . The receptor subtypes differ in amino acid sequence, signaling mechanisms, and tissue distribution (Howlett 2002) . CB 1 receptors are seven transmembranespanning receptors coupled to the Gi/o class of G-proteins, are widely distributed in brain (e.g., Herkenham et al. 1991; Gifford et al. 1999) , and are generally thought to mediate the high produced by marijuana as well as most other centrally mediated effects of the cannabinoids.
CB 1 receptor agonists vary in the maximum to which they stimulate G-protein-coupled signaling (i.e., agonist efficacy), as evidenced by [ 35 S] guanosine 5′-3′thio-triphosphate (GTPγS) binding in rodent brain tissue, with the following rank order: CP 55940>anandamide>Δ 9 -THC (Breivogel and Childers 2000; Childers 2006 ). However, in vivo, even low efficacy agonists such as Δ 9 -THC often produce the same maximum effect as that obtained with high efficacy agonists (e.g., Fan et al. 1994) , perhaps reflecting the large number of cannabinoid receptors (i.e., spare receptors) in the central nervous system (Gifford et al. 1999 ). According to receptor theory (Kenakin 1997 (Kenakin , 2002 , low efficacy agonists occupy more CB 1 receptors than high efficacy agonists at equal levels of effect. In addition to agonists differing in efficacy, different in vivo effects might require increasing levels of CB 1 receptor activation or efficacy which, in turn, could result in a decrease in potency. In other words, when the CB 1 agonist efficacy required for an effect is relatively low, smaller doses are sufficient, whereas larger doses might be required to produce an effect requiring relatively high efficacy. If cannabinoid efficacy is important in vivo, then loss of receptor function should be accompanied by a greater decrease in sensitivity (i.e., tolerance and crosstolerance) to a low efficacy agonist as compared with a higher efficacy agonist. Moreover, loss of sensitivity to an effect requiring high efficacy will be greater as compared to another effect requiring lower efficacy. Numerous mechanisms have been implicated in loss of CB 1 receptor function including receptor dimerization, changes in G-proteins and other proteins involved in second messenger signaling, receptor internalization, and receptor loss . Because chronic CB 1 receptor agonist treatment has been repeatedly shown to decrease CB 1 receptor function (Dill and Howlett 1988; Oviedo et al. 1993; Rodríguez de Fonseca et al. 1994; Coutts et al. 2001) , such treatment was chosen in the current study to examine relationships between efficacy and effect.
The current study compared not only in vivo effects of cannabinoids (Δ 9 -THC, CP 55940, and anandamide) that vary in agonist efficacy in vitro (Breivogel and Childers 2000; Childers 2006 ) but also two in vivo effects (decreases in schedule-controlled responding and hypothermia) that vary in their sensitivity to cannabinoids and, perhaps, efficacy required for agonist activity. Male C57BL/6J mice were trained to respond under an FR30 schedule of food presentation; rectal temperature was obtained during operant sessions. Sensitivity of the mice to the cannabinoids and a non-cannabinoid (the benzodiazepine midazolam) was determined before, during, and after discontinuation of Δ 9 -THC treatment (32 mg/kg/day i.p.). In a previous study (Giuffrida and McMahon 2010) , the CB 1 antagonist rimonabant dose-dependently antagonized the hypothermic effects of Δ 9 -THC and CP 55940, demonstrating involvement of CB 1 receptors. However, even though anandamide is a CB 1 agonist (Devane et al. 1992) , its hypothermic effects were not antagonized by rimonabant (Adams et al. 1998; Giuffrida and McMahon 2010) . In the current study, rimonabant was combined with the agonists to evaluate the role of CB 1 receptors in cannabinoid-induced decreases in fixed ratio responding in mice. Collectively, these studies tested the hypothesis that daily Δ 9 -THC treatment would produce a greater loss of sensitivity to low as compared with high efficacy CB 1 agonists and, further, would produce a greater loss of sensitivity to effects requiring high CB 1 agonist efficacy as compared with effects requiring lower agonist efficacy.
Materials and methods

Subjects
Male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) were purchased at 5 weeks of age (approximately 15 g) and were housed individually on a 14/10-h light/dark cycle. Mice were maintained at 85% of free-feeding weight and received approximately 1 cm 3 of a 1-to-1 mixture of condensed milk and tap water during experimental sessions and 2.5 g of food (Dustless Precision Pellets 500 mg, Rodent Grain-Based Diet; BioServ, Frenchtown, NJ, USA) per day after sessions; water was available ad libitum in the home cage. Mice were habituated to the experimental room for 7 days before the first experimental session, and testing was conducted during the light period. Mice were maintained, and experiments were conducted in accordance with the Institutional Animal Care and Use Committee, The University of Texas Health Science Center at San Antonio, and with the "Principles of Laboratory Animal Care" and the "Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research" (National Research Council 2003) .
Apparatus
Commercially available mouse operant conditioning chambers (MedAssociates, St. Albans, VT, USA) were placed in ventilated, sound-attenuating enclosures. The ceiling of each operant conditioning chamber contained a light (i.e., house light) and the side of one wall contained a recessed hole (2.2-cm diameter). The center of the hole was positioned 1.6 cm from the floor. The hole contained a photo beam, a light, and a dipper to which 0.01 cm 3 of condensed milk could be delivered from a tray positioned outside the operant conditioning chamber. An interface (MedAssociates) connected the operant conditioning chambers to a computer, and experimental events were con-trolled and recorded with Med-PC software. Temperature was measured by inserting a probe 2 cm into the rectum; a digital recording was obtained from a commercially available thermometer (model BAT-7001H; Physitemp Instruments, Inc., Clifton, NJ, USA).
Operant conditioning procedure
Sessions were conducted once daily 7 days per week. Mice initially responded under a schedule of continuous reinforcement. The hole containing the photobeam was illuminated and mice could insert their snouts to disrupt the photobeam; disruption of the photobeam resulted in 10-s access to 0.01 cm 3 of milk. During 10-s access to milk, the light in the recessed hole was turned off and the house light was illuminated. Disruptions of the photobeam during the 10-s period of milk availability had no programmed consequence. Training under the schedule of continuous reinforcement was conducted for three sessions; sessions ended when 100 reinforcers were earned or after 30 min, whichever occurred first. Thereafter, the fixed ratio requirement was increased every three sessions to an FR3, FR10, and FR30. After three sessions at FR30, sessions were divided into 20-min, consecutive cycles. Each cycle began with a 15-min pretreatment, during which time the chamber was dark and responding had no programmed consequence. The 15-min pretreatment was followed by a 5-min period of milk availability under the FR30 schedule. Mice received intraperitoneal injections of vehicle in the first minute of the first cycle, followed by vehicle or sham injections (dull pressure applied to abdominal area) non-systematically in the first minute of subsequent cycles. Training was conducted until mean response rate during a session was ±20% of the mean response rate for all cycles in the five preceding sessions. After satisfying this criterion, drugs were administered during sessions; successive drug tests were conducted only when responding during the immediately preceding non-drug session was ±20% of the mean rate for all cycles during the five previous non-drug sessions.
Tests with rimonabant in combination with cannabinoid agonists
The effects of rimonabant in combination with Δ 9 -THC, CP 55940, and anandamide were examined using a withinsubjects design. The effects of Δ 9 -THC in combination with rimonabant were examined in seven mice. Three of these mice and four other pharmacologically naïve mice (i.e., not tested with Δ 9 -THC) were used to examine the effects of rimonabant in combination with CP 55940 and anandamide. A control dose-response curve (i.e., agonist alone) was determined first, followed by studies with that agonist in the presence of three doses (1, 3.2, and 10 mg/kg, i.p.) of rimonabant; the order of testing with various doses of rimonabant was non-systematic. A second control doseresponse curve was determined after studies with rimonabant. This sequence of testing (i.e., agonist alone, followed by agonist in combination with rimonabant, followed by agonist alone) was completed for one agonist before initiating the sequence with a second agonist. Agonist dose-response functions were determined by administering vehicle or a dose of rimonabant at the beginning of the first cycle, followed by cumulative doses of agonist increasing by 0.25 or 0.5 log unit per cycle. The number of cycles for a test was determined by the number of cycles required to complete the dose-effect curve (i.e., from an ineffective dose to a dose that resulted in fewer than 30 responses during a cycle).
Tests with cannabinoids and a non-cannabinoid before, during, and after discontinuation of daily
The four mice that had been tested with rimonabant in combination with acute Δ 9 -THC (see above), and three other pharmacologically naïve mice, were used to examine the effects of daily Δ 9 -THC treatment. Mice were trained to respond under an FR30 schedule of milk presentation during six, consecutive 20-min cycles as described above. Before drug tests, mice received saline or sham at the beginning of cycles and rectal temperature was measured at the end of each cycle until responding stabilized, defined as five consecutive days with response rate within ±20% of the mean rate for those days. After satisfying this criterion, control dose-response curves for Δ 9 -THC, CP 55940, anandamide, and midazolam were determined by administering vehicle at the beginning of the first cycle followed by cumulative doses in subsequent cycles. Successive drug tests were conducted only when responding during the immediately preceding non-drug session was ±20% of the mean rate for all cycles during the five previous non-drug sessions. The number of cycles for a test depended on the number of cycles required to complete a dose-effect curve for hypothermic effects, i.e., from an ineffective dose to a dose that produced maximum hypothermia as determined previously (Giuffrida and McMahon 2010) . The order of testing with the various drugs was non-systematic.
For studies with daily Δ 9 -THC, a dose of 32 mg/kg/day was chosen. When administered acutely, this dose (32 mg/kg) of Δ 9 -THC suppressed responding for up to 4 h; therefore, a 6-h pretreatment was chosen so that mice would respond during experimental sessions. Fifty-six days elapsed between the first and last day of Δ 9 -THC treatment; however, on days when drugs were administered in cumulative doses during the session, Δ 9 -THC treatment was omitted (i.e., mice received an injection of vehicle 6 h before the session). On days when Δ 9 -THC (32 mg/kg) was administered 6 h before sessions, mice received vehicle or sham at the beginning of two to six cycles with the number of cycles varying non-systematically across days. Dose-response curves were determined in a single session by administering vehicle in the first cycle followed by cumulative doses in subsequent cycles. Dose-response curves for Δ 9 -THC were determined on days 8, 15, and 54 of daily treatment. For other drugs, dose-response curves were determined between days 15 and 54 of daily treatment and when response rate during the immediately preceding session was ±20% of the mean rate for all cycles during the five previous sessions, excluding days on which Δ 9 -THC (32 mg/kg) treatment was omitted. Drugs were studied up to doses that markedly decreased response rate; doses larger than 56 mg/kg Δ 9 -THC and 3.2 mg/kg CP 55940 were not studied to minimize disruption in operant responding on the following day. During Δ 9 -THC treatment, the order of testing with CP 55940, anandamide, and midazolam was non-systematic.
Daily Δ 9 -THC treatment was discontinued by administering vehicle instead of sham before daily sessions; vehicle or sham was administered at the beginning of cycles on days when drugs were not administered. A dose-response curve was re-determined for Δ 9 -THC on day 9 of the discontinuation period. Thereafter, dose-response curves for CP 55940, anandamide, and midazolam were determined in non-systematic order when response rate during the immediately preceding session was ±20% of the mean rate for all cycles during the five previous non-drug sessions.
Drugs
Rimonabant and Δ 9 -THC (100 mg/ml in absolute ethanol) were obtained from The Research Technology Branch, National Institute on Drug Abuse (Rockville, MD, USA); CP 55940 was obtained from Tocris (Ellisville, MO, USA). Anandamide was synthesized according to a protocol developed by Giuffrida and Piomelli (1998a) ; the final product was analyzed with gas chromatography and mass spectrometry as described (Giuffrida and Piomelli 1998b; Hardison et al. 2006) . The ethanol was evaporated and rimonabant, Δ 9 -THC, CP 55940, and anandamide were dissolved in a mixture of one part propylene glycol (Sigma), one part Tween 80 (Sigma), and 18 parts physiologic saline. Midazolam hydrochloride (5 mg/ml in physiologic saline; Bedford Laboratories, Bedford, OH, USA) was diluted in physiologic saline as needed. All drugs were administered i.p. in a volume of 10 ml/kg and dose was expressed as the weight of the forms listed above in milligrams per kilogram of body weight.
Data analysis
Control rate of responding (responses per second) was calculated as the average rate for all cycles in the five nondrug (i.e., vehicle) sessions immediately preceding a drug session. Control response rate, with and without measurement of rectal temperature, was compared with a paired t test (p <0.05). Response rate data were plotted and analyzed as a percentage of the control response rate. The effects of drugs to decrease body temperature were plotted as the change from the vehicle control in degrees Celsius. Differences in maximum hypothermic effect among drugs were analyzed with repeated measures oneway ANOVA and Tukey all pair-wise comparison procedure (p <0.05). To compare the potency of drugs to produce hypothermia, dose-response data for each drug were converted to a percentage of the maximum effect determined for each respective drug before daily Δ 9 -THC treatment. Potency was calculated by simultaneously fitting straight lines to individual dose-effect data by means of GraphPad Prism version 5.0 for Windows (San Diego, CA, USA) with linear regression. Straight lines were fitted to the linear portion of dose-effect curves. The slopes of dose-effect curves were compared with an F-ratio test using GraphPad; if the slopes were not significantly different, then a common, best-fitting slope was used for further analyses (Kenakin 1997) . Doses corresponding to the 50% level of the effect (ED 50 values), potency ratios, and their 95% confidence limits were calculated with parallel line analyses of data from individual subjects (Tallarida 2000) . The potencies were considered significantly different when the 95% confidence limits of the potency ratio did not include 1.
Relatively large doses of rimonabant tended to decrease response rate when administered before cumulative doses of agonist; therefore, the effects of rimonabant in combination with Δ 9 -THC, CP 55940, and anandamide were analyzed by expressing data as a percentage of the response rate following each respective dose of rimonabant alone.
Results
Control performance and rate-decreasing effects of cannabinoid agonists alone and in combination with rimonabant When response rate for five non-drug sessions were averaged for individual mice, the median value of absolute response rate among mice (n=14) was 2.9 responses per second; the range was 1.1-4.8 responses per second. Response rate did not significantly vary as a function of whether rectal temperature was measured during the experimental session (n=7; mean=2.9 responses per sec-ond; SEM=0.41) or not (n=7; mean=3.1 responses per second; SEM=0.51) (p>0.05).
Vehicle i.p. did not significantly modify response rate, whereas Δ 9 -THC, CP 55940, and anandamide dosedependently decreased response rate (Fig. 1) . For example, response rate was decreased to less than 20% of control by Δ 9 -THC at a dose of 17.8 mg/kg, CP 55940 at a dose of 0.32 mg/kg, and anandamide at a dose of 10 mg/kg. The two control agonist dose-response functions (i.e., ED 50 values), one determined before and the other after the agonist was combined with various doses of rimonabant, were not significantly different from each other (p>0.05); therefore, the data were averaged for graphic presentation (Fig. 1) and further analysis. The slopes of the doseresponse curves were not significantly different (p>0.05); CP 55940 (ED 50 value=0.10 mg/kg) was 39-fold more potent than anandamide (ED 50 value=3.9 mg/kg), which was 2-fold more potent than Δ 9 -THC (ED 50 value=7.5 mg/kg) (Table 1) .
Rimonabant, up to the largest dose (10 mg/kg) studied, decreased response rate to a maximum of 47% (Fig. 2, top , square above VEH). The slopes of the Δ 9 -THC doseresponse curves alone and in combination with various doses of rimonabant were not significantly different (p> 0.05). Rimonabant dose-dependently antagonized the effects of Δ 9 -THC to decrease responding, albeit the magnitude of antagonism was relatively small (Fig. 2,  top) . Rimonabant (3.2 mg/kg) significantly decreased the potency of Δ 9 -THC 2.4-fold (Table 1) ; the smaller and larger doses (1 and 10 mg/kg, respectively) of rimonabant did not produce significant antagonism. The slopes of the CP 55940 dose-response curves alone and in combination with various doses of rimonabant were not significantly different. Rimonabant produced similar antagonism of the rate-decreasing effects of CP 55940. There was a tendency for each dose of rimonabant to produce some antagonism of the rate-decreasing effects of CP 55940 (Fig. 2, middle) ; however, only a dose of 1 mg/kg of rimonabant significantly increased the ED 50 value of CP 55940 ( Table 1 ). The slopes of the anandamide dose-response curves alone and in combination with rimonabant did not significantly differ; however, in contrast to Δ 9 -THC and CP 55940, rimonabant did not antagonize the rate-decreasing effects of anandamide (Fig. 2, bottom) . Rather, a dose of 3.2 mg/kg of rimonabant significantly increased the potency of anandamide (Table 1) .
Rate-decreasing and hypothermic effects of drugs before, during, and after discontinuation of daily Δ 9 -THC (32 mg/kg/day) When examined for each drug separately, the slopes of the dose-response curves determined before, during, and after discontinuation of daily Δ 9 -THC (32 mg/kg/day) treatment were not significantly different. Similarly, for hypothermia, the slopes of the anandamide dose-effect curves did not significantly differ; however, the slopes were significantly different for the dose-response curves for Δ 9 -THC and CP 55940 to produce hypothermia (p<0.05). Before daily treatment, Δ 9 -THC, CP 55940, and anandamide dose-dependently decreased response rate (Fig. 3, top) . The ED 50 values were 5.64 mg/kg for Δ 9 -THC, 0.12 mg/kg for CP 55940, and 5.45 mg/kg for anandamide (Table 2 ). These ED 50 values were comparable to those obtained when not measuring rectal temperature (see Table 1 ). Δ 9 -THC, CP 55940, and anandamide dose-dependently decreased body temperature (Fig. 3, bottom) ; the largest doses tested (i.e., 32 mg/kg, 3.2 mg/kg, and 56 mg/kg, respectively) also produced the maximum decrease in rectal temperature, which was 2.6°C for Δ 9 -THC, 8.9°C for CP 55940, and 5.4°C for anandamide. The maximum hypothermic effect of Δ 9 -THC was significantly less than the maximum obtained with anandamide which, in turn, was significantly less than the maximum produced by CP 55940 (F 2,12 = 52.84; p<0.001). For each drug, the ED 50 value for decreasing rectal temperature was greater (i.e., between 1.8-and 4.0-fold) than its respective ED 50 value for decreasing response rate ( Table 2) .
Administration of 32 mg/kg of Δ 9 -THC 6 h before the session decreased response rate to 19% of control ( Fig. 4 ; top, compare day 1 of During to Before) and also decreased temperature by 2.1°C relative to temperature measured the day before (i.e., when vehicle was administered; Fig. 4 , bottom). Response rate continued to be decreased between days 2 and 7 of Δ 9 -THC (32 mg/kg/day) treatment. From day 11 until the last day of treatment, there was an incomplete loss of sensitivity to the rate-decreasing effects of Δ 9 -THC, which appeared to be steady throughout that period; the median response rate was 63% of control and the range was 43-78% of control. In contrast, loss of sensitivity to the hypothermic effects of Δ 9 -THC occurred more rapidly (i.e., by day 2 of treatment); from day 2 until the end of treatment, the median decrease in temperature was 0.6°C and the range was 0.1-1.1°C. During Δ 9 -THC treatment (32 mg/kg/day), there was a significant decrease in the potency of Δ 9 -THC to reduce response rate. For example, on day 15 of treatment, the potency of Δ 9 -THC was decreased 8.2-fold (Fig. 3 , top left, compare triangles to circles). On days 8 and 54 of treatment, potency also was significantly decreased 7.6-and 1.9-fold, respectively. In contrast, the potency of CP 55940 and anandamide to decrease response rate were not significantly modified by Δ 9 -THC treatment (Fig. 3 , top middle and right, respectively; Table 2 ). The slopes of the midazolam dose-response curves determined before and during Δ 9 -THC treatment were significantly different (p<0.05) (Fig. 5, top) ; due to the relatively steep slope of the curve determined during treatment as compared with that determined before treatment, the ED 50 values could not be readily compared.
The potency of Δ 9 -THC to produce hypothermia also was decreased during Δ 9 -THC treatment; up to the largest dose (56 mg/kg), the maximum decrease in temperature was 0.7°C (Fig. 3 , bottom left, compare triangles to circles). In contrast to the absence of a change in sensitivity to the rate-decreasing effects of CP 55940, sensitivity to the hypothermic effects of CP 55940 was markedly decreased during Δ 9 -THC treatment (Fig. 3, bottom middle) . Up to the largest dose (3.2 mg/kg), the maximum decrease in temperature was −1.6°C. The ED 50 values of Δ 9 -THC and CP 55940 during treatment were not calculated because the maximum effect was not greater than 50% of that established before treatment. The ED 50 values for anandamide and midazolam to produce hypothermia were not significantly modified during Δ 9 -THC treatment (Fig. 3 , bottom right and Fig. 5 , bottom, respectively; Table 2 ). When Δ 9 -THC treatment was discontinued, response rate returned to control levels (Fig. 4, After) . On day 9 of the discontinuation period, the potency of Δ 9 -THC to decrease response rate and body temperature was greater than it was during Δ 9 -THC treatment, although the potency remained significantly less than the control (i.e., that determined before treatment) (Fig. 3, top and bottom left, compare squares and circles; Table 2 ). The ED 50 value of CP 55940 to decrease response rate after discontinuation of Δ 9 -THC treatment was not significantly different from control. Although the potency of CP 55940 to produce hypothermia after discontinuation was significantly less than control (Table 2) , the potency was greater than it was during Δ 9 -THC treatment (Fig. 3 , bottom middle, compare squares and circles). The ED 50 values for anandamide and midazolam, determined for both rate-decreasing and hypothermic effects after discontinuation of treatment, did not significantly differ from control (Fig. 3, right and Fig. 5 , respectively; Table 2 ).
Discussion
In C57BL/6J mice, the effects of Δ 9 -THC and CP 55940 to decrease fixed ratio responding for food were antagonized by the CB 1 antagonist rimonabant; however, antagonism was limited by the rate-decreasing effects of rimonabant alone, as has been reported previously in rats (Järbe et al. -THC (left), CP 55940 (middle), and anandamide (right) to decrease responding for food (top panels) and to produce hypothermia (bottom panels) before (circles), during (triangles), and after discontinuation (squares) of daily Δ 9 -THC (32 mg/kg) treatment in mice. Abscissae vehicle (VEH) or i.p. dose in milligrams per kilogram of body weight. Ordinates mean (±SEM) rate of responding expressed as a percentage of control (top) and mean (±SEM) change in body temperature as degrees Celsius (bottom) 2003; . In contrast, the ratedecreasing effects of anandamide were not blocked by rimonabant, suggesting that CB 1 receptors were not involved. Daily Δ 9 -THC treatment produced tolerance but not cross-tolerance to CP 55490 when measuring ratedecreasing effects, consistent with CP 55940 having higher agonist efficacy than Δ 9 -THC in vitro (Breivogel and Childers 2000) . For hypothermic effects, both tolerance to Δ 9 -THC and cross-tolerance to CP 55940 developed. The greater loss of sensitivity to the hypothermic as compared to the rate-decreasing effects of CP 55940 suggests that the former requires greater CB 1 agonist efficacy as compared with the latter. Δ 9 -THC treatment did not modify sensitivity to anandamide or a benzodiazepine (midazolam). Collectively, these results suggest that the magnitude of tolerance/cross-tolerance to cannabinoids is a function of the CB 1 efficacy of the agonists to which tolerance/crosstolerance develops, and also as a function of the efficacy required to produce different effects in vivo.
Receptor theory predicts that loss of receptor function differentially impacts sensitivity to agonists on the basis of efficacy (Kenakin 1997) . For an effect to be maintained when receptor function is decreased, percent receptor occupancy (i.e., fractional occupancy) and dose increases (i.e., tolerance and cross-tolerance develop). However, because a low efficacy agonist occupies more receptors than a higher efficacy agonist when their effects are equivalent, loss of receptor function produces a disproportionately greater increase in fractional occupancy (i.e., tolerance/cross-tolerance) for a low as compared to a high Selley et al. 2004; Pertwee et al. 1993) . Here, the greater tolerance to Δ 9 -THC as compared with cross-tolerance to CP 55940 provides evidence that differences in the capacity of these agonists to stimulate inhibitory G proteins (i.e., CB 1 agonist efficacy; Breivogel and Childers 2000) are important for behavioral effects. Although the current study did not measure CB 1 receptor function directly, an assumption is made, based on several previous studies, that daily Δ 9 -THC treatment decreased Gprotein signaling at CB 1 receptors as a result of receptor loss and/or internalization and also desensitization resulting from receptor dimerization and changes to both G-and non-G-proteins (Sim et al. 1996; Breivogel et al. 1999 Breivogel et al. , 2003 Selley et al. 2004; Falenski et al. 2010; Smith et al. 2010) .
CP 55940 was more potent than Δ 9 -THC (current results; Martin et al. 1991 ) and the potency of both for decreasing operant responding was greater than that for producing hypothermic effects. This difference in potency for producing two effects might reflect differential binding to multiple receptor subtypes that differentially mediate the two effects. However, rimonabant antagonized the ratedecreasing and hypothermic effects of Δ 9 -THC and CP 55940 (current results; Giuffrida and McMahon 2010) , albeit antagonism of rate-decreasing effects was less orderly and of a lesser magnitude than antagonism of hypothermia. Less orderly antagonism of rate-decreasing effects could reflect actions of rimonabant at a subset of brain cannabinoid receptors that are more prominently involved in ratedecreasing effects than hypothermic effects; however, mechanisms underlying the effects of rimonabant are not known. Alternatively, if both rate-decreasing and hypothermic effects are mediated by the same receptor type (e.g., CB 1 ), then the difference in potency might be due to a difference in the magnitude of CB 1 receptor stimulation (i.e., the efficacy requirement) required for the effects (i.e., hypothermic>rate-decreasing effects). The marked crosstolerance from Δ 9 -THC to CP 55940 that developed for hypothermic effects in the absence of a similar crosstolerance from Δ 9 -THC to CP 55940 for rate-decreasing effects is consistent with a difference in the efficacy requirement. Likewise, the greater tolerance to Δ 9 -THC for hypothermic effects as compared with rate-decreasing effects is consistent with a difference in the CB 1 agonist efficacy required for the two effects (se also for differential tolerance to CP 55940). These results provide empirical support for receptor theory, which predicts that loss of sensitivity is greater for an effect associated with high receptor occupancy and few spare receptors as compared to an effect associated with lower receptor occupancy and more spare receptors.
Anandamide reportedly has CB 1 agonist efficacy intermediate to that of Δ 9 -THC and CP 55940 (Childers 2006 ) and was included for study to better assess the relationship between efficacy and tolerance/cross-tolerance. However, Response rate (top) and rectal temperature (bottom) before, during, and after discontinuation of daily Δ 9 -THC (32 mg/kg) treatment in mice. Abscissae consecutive days before, during, and after discontinuation of daily Δ 9 -THC treatment. Ordinates mean (±SEM) rate of responding expressed as a percentage of control (top) and mean (±SEM) body temperature as degrees Celsius (bottom) the effects of anandamide were not mediated by Δ 9 -THCand CP 55940-sensitive receptors as evidenced by failure of rimonabant to antagonize the rate-decreasing and hypothermic effects of anandamide (current results; Giuffrida and McMahon 2010) and, further, by failure of daily Δ 9 -THC treatment to produce cross-tolerance to anandamide. Even though anandamide did not act at CB 1 receptors, its inclusion with midazolam further strengthened the notion that Δ 9 -THC treatment selectively decreased the effects of CB 1 agonists. The results of drug discrimination studies strongly suggest that the in vivo effects of anandamide diverge from prototypic cannabinoid agonists (Wiley et al. 1995 (Wiley et al. , 1997 Järbe et al. 2001; Solinas et al. 2007; Giuffrida and McMahon 2010) . However, exceptions have been noted previously; anandamide shared discriminative stimulus effects with Δ 9 -THC in monkeys (McMahon 2009) and tolerance to Δ 9 -THC was accompanied by lesser cross-tolerance to anandamide and chemical analogs of anandamide (Wiley et al. 2006) . One parsimonious explanation is that the rate of anandamide metabolism and subsequent contribution of non-CB 1 receptor-acting metabolites (Willoughby et al. 1997; Wiley et al. 2006) both vary as a function of species and/or route of administration. Unless strategies are used to inhibit metabolism, anandamide appears to have limited utility as a probe for CB 1 receptors, at least when administered systemically in rodents. Accordingly, by decreasing anandamide metabolism through transgenic deletion or pharmacologic inhibition of fatty acid amide hydrolase, the effects of anandamide are more clearly CB 1 receptor-mediated (Cravatt et al. 2001; Solinas et al. 2007 ) to include lesser crosstolerance from Δ 9 -THC to anandamide than tolerance to Δ 9 -THC (Falenski et al. 2010 ), a finding consistent with the current results. In addition to the magnitude of tolerance/ cross-tolerance being related to CB 1 efficacy, other interpretations have been provided (Wiley et al. 2006 ) to include differential changes in brain anandamide levels (Di Marzo et al. 2000) which could, in turn, have different effects on sensitivity to anandamide versus Δ 9 -THC and other cannabinoid agonists not derived from brain.
In summary, the results of this study show a relationship between the magnitude of tolerance/cross-tolerance and the apparent CB 1 agonist efficacy of cannabinoids to which tolerance/cross-tolerance develops. Marijuana smoking or oral Δ 9 -THC administration presumably decreases CB 1 receptor function, and the current results indicate that loss of sensitivity to cannabinoids will be greater for low efficacy cannabinoid agonists, such as Δ 9 -THC, than to higher efficacy cannabinoid agonists. In addition to differential changes in sensitivity among agonists that vary with efficacy, this study further suggests that receptor occupancy and efficacy can vary for different in vivo effects of the cannabinoids. In particular, as the dose needed for effect increases, the CB 1 agonist efficacy requirement also increases. Loss of CB 1 receptor function will produce a greater decrease in sensitivity to effects that require high levels of CB 1 receptor stimulation as compared to effects requiring less CB 1 receptor stimulation. Therapeutic effects (e.g., antinociceptive) of CB 1 agonists that appear to require relatively high efficacy might be more susceptible to the development of tolerance than other effects associated with lower efficacy, which might include effects (discriminative stimulus and subjective effects) associated with the abuse liability of CB 1 agonists.
